Skin-resident antigen-presenting cells play an important role in maintaining peripheral tolerance via immune checkpoint proteins and induction of T regulatory cells (Tregs). However, we lack knowledge on how to expand or recruit immunoregulatory cutaneous cells without causing inflammation.
The consortium will establish in vitro and in vivo models to evaluate new antiviral compounds active against SARS-CoV-2. The aim is to develop broad-spectrum antivirals that can be administered locally to the nose and/or lungs.
We will map local immune responses in the lungs of mice infected with RSV and compare the responses occurring after treatment using an oligonucleotide with capacity to inhibit RSV infection.
